Gland Pharma Share Price Surges on Regulatory Boost for Telangana Unit

Market Performance

Gland Pharma's share price witnessed a notable uptick in Monday's trading session following a regulatory milestone.

The stock surged as much as 2.12% intraday, reaching ₹1,898.4, marking its sharpest rise since July 1, 2025.

• As of 9:40 AM, the stock was up 1.27%, trading at ₹1,882.7 per share.
• This came despite a 0.30% drop in the Nifty 50 index
• Gland Pharma shares are now at their highest level since January 7, 2025
• The counter is currently trading at 4 times its 30-day average volume
• So far in 2025, the stock has gained 5.5%, compared to 6% in the Nifty 50

The rise in Gland Pharma's share price aligns with investor optimism following the regulatory update.

Main Development

Gland Pharma Ltd. announced that its Pashamylaram facility in Telangana has secured Good Manufacturing Practices (GMP) certification from the Danish Medicines Agency.

This certification further strengthens the company's regulatory compliance credentials in global markets.

The certification is expected to facilitate better access to European markets for the Telangana unit, enhancing the firm's credibility in international pharmaceutical supply chains.

Financial Overview

Revenue

• Gland Pharma reported a 7% YoY decline in revenue for Q4FY25.
• Revenue stood at ₹1,424.9 Crore, down from ₹1,537.5 Crore in Q4FY24

EBITDA

• The company posted an EBITDA of ₹347.5 Crore in Q4FY25.
• This represents a marginal dip from ₹358.7 Crore in the previous year.

Net Profit

• Net profit for Q4FY25 declined 3% YoY.
• The company reported earnings of ₹186.5 Crore in consolidated net profit for the quarter, showing a modest decline from ₹192.4 Crore in the corresponding quarter last year.

Company Background

Gland Pharma is a leading generic injectables-focused pharmaceutical company with a presence in over 60 countries.

Its product portfolio spans sterile injectables, oncology, and ophthalmics, targeting complex delivery systems.

Key Highlights:

• Operates seven manufacturing facilities across India
  • 4 for finished formulations
  • 3 for Active Pharmaceutical Ingredients (API)
• Markets span the US, Europe, Canada, Australia, India, and other global regions.

The company's strategic focus lies in producing complex injectable products across various therapeutic segments.

Summary

The recent rise in Gland Pharma's share price follows the Danish Medicines Agency's GMP approval for its Telangana unit, enhancing its regulatory stature in global markets.

Despite modest financial performance in Q4FY25, the company's operational expansion and international footprint continue to offer long-term strategic positioning.

With the stock currently outperforming its recent trends and trading at multi-month highs, Gland Pharma remains in investor focus amid growing international recognition.